张阳, 杨金伟, 李兴德, 等. miR-155在器官移植排斥反应中的作用研究进展[J]. 器官移植, 2022, 13(5): 666-671. DOI: 10.3969/j.issn.1674-7445.2022.05.018
引用本文: 张阳, 杨金伟, 李兴德, 等. miR-155在器官移植排斥反应中的作用研究进展[J]. 器官移植, 2022, 13(5): 666-671. DOI: 10.3969/j.issn.1674-7445.2022.05.018
Zhang Yang, Yang Jinwei, Li Xingde, et al. Research progress on the role of miR-155 in rejection of organ transplantation[J]. ORGAN TRANSPLANTATION, 2022, 13(5): 666-671. DOI: 10.3969/j.issn.1674-7445.2022.05.018
Citation: Zhang Yang, Yang Jinwei, Li Xingde, et al. Research progress on the role of miR-155 in rejection of organ transplantation[J]. ORGAN TRANSPLANTATION, 2022, 13(5): 666-671. DOI: 10.3969/j.issn.1674-7445.2022.05.018

miR-155在器官移植排斥反应中的作用研究进展

Research progress on the role of miR-155 in rejection of organ transplantation

  • 摘要: 排斥反应一直是器官移植研究领域中难以彻底攻克的难题。排斥反应的机制研究对提高移植效果以及移植物的存活率十分重要。机体的固有免疫应答和特异性免疫应答协同参与了移植排斥反应,造成移植物损伤。近年来许多研究者对微小核糖核酸(miR)调控排斥反应的机制进行了深入研究,其中miR-155被广泛认为是参与免疫调节的关键因子,其表达水平和功能状态可能与排斥反应的发生密切相关,因而有可能成为克服机体排斥反应的新靶点。本文就miR-155对固有免疫和特异性免疫应答中关键免疫细胞的调控相关研究进行综述,为新型免疫抑制药开发和排斥反应治疗提供新思路。

     

    Abstract: Rejection has constantly been an unresolved challenge in the field of organ transplantation. The research on the mechanism of rejection plays a significant role in improving the efficacy of organ transplantation and enhancing the survival rate of graft. The innate and specific immune responses of the human body jointly participate in the graft rejection, leading to graft injury. In recent years, multiple researchers have conducted in-depth studies on the mechanism underlying the role of microRNA (miR) in regulating rejection. Among them, miR-155 has been widely considered as a key factor involved in immune regulation. The expression level and functional status of miR-155 may be intimately associated with the occurrence of rejection, which may become a new target for overcoming rejection. In this article, relevant studies on the role of miR-155 in regulating key immune cells in innate and specific immune responses were reviewed, aiming to provide novel ideas for the development of new immunosuppressants and rejection therapy.

     

/

返回文章
返回